Hyperhomocysteinemia Due to Pernicious Anemia Leading to Pulmonary Thromboembolism in a Heterozygous Mutation Carrier

Abstract

Pulmonary thromboembolism is a life-threatening condition resulting mostly from lower extremity deep-vein or pelvic-vein thrombosis. A 46-year-old woman was admitted to hospital with pain on the right side of the chest and hemoptysis. On laboratory analysis, D-dimer level was elevated. Computed tomographic pulmonary angiography revealed intravascular filling defects due to thrombi in right lower lobe pulmonary segmental arteries. Screening for thrombophilic states was normal except for heterozygous mutations of both prothrombin and methylene tetrahydrofolate reductase (MTHFR 677) genes. Homocysteine level was high, and vitamin B12 level and serum ferritin level were reduced. Serum antiparietal antibody was positive, and therefore, pernicious anemia was diagnosed along with iron-deficiency anemia. After the diagnoses were established, enoxaparin followed by warfarin was started in addition to oral vitamin B12, pyridoxine, thiamine, folic acid, and ferroglycine sulfate supplementation. At the end of 8 weeks of the replacement therapy, vitamin B12, folate, and homocysteine levels and red cell volume were found to be normal, with complete resolution of the thrombus confirmed by repeat computed tomographic pulmonary angiography. We conclude that hyperhomocysteinemia due to vitamin B12 deficiency associated with pernicious anemia might have decreased the threshold for thrombosis. In addition, the presence of heterozygous prothrombin and methylene tetrahydrofolate reductase mutations might serve as synergistic cofactors triggering pulmonary thromboembolism.

Keywords

pulmonary thromboembolism hyperhomocysteinemia pernicious anemia

References

British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax. 2003;58:470-484.

Hainaut P. , Jaumotte C. , Verhelst D. , et al. Hyperhomocysteinemia and venous thromboembolism: a risk factor more prevalent in elderly and in idiopathic cases. Thromb Res. 2002;106:121-125.

den Heijer M. , Koster T. , Blom HJ , et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996 ;334:759-762.

Ray JG Meta-analyses of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med. 1998;158:2101-2106.

den Heijer M. , Rosendaal FR , Blom HJ , Gerrits WB , Bos GM Hyperhomocysteinemia and venous thrombosis: a meta-analyses. Thromb Haemost. 1998;80:874-877.

McCully KS Homocysteine and vascular disease. Nat Med. 1996;2:386-389.

Eichinger S. , Stümpflen A. , Hirshl M. , et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost. 1998;80: 566-569.

Langman LJ , Ray JG , Evrovski J. , Yeo E. , Cole DE Hyperhomocysteinemia and the increased risk of venous thromboembolism. Arch Intern Med. 2000;160:961-964.

Dani SI , Thanvi S. , Shah JM , Prajapti J. , Jain S. , Joshi H. Hyperhomocysteinemia masquerading as pulmonary embolism. JAPI. 2003;51:914-915.

10.

Caldera A. , Mora J. , Kottler M. , Eiger G. Pulmonary embolism in a patient with pernicious anemia and hyperhomocysteinemia . Chest. 2002;122:1487-1488.

11.

Eichinger S. , Minar E. , Hirschl M. , et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost. 1999;81:14-17.

12.

Baglin T. , Luddington R. , Brown K. , Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet . 2003;362:523-526.

13.

Tsai AW , Cushman M. , Tsai MY , et al. Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: longitudinal investigation of thromboembolism etiology (LITE). Am J Hematol. 2003;72:192-200.

14.

Brown K. , Luddington R. , Baglin T. Effect of the MTHFRC677T variant on risk of venous thromboembolism: interaction with factor V leiden and prothrombin (F2G20210A) mutations. Br J Haematol. 1998;79: 254-258.